MA44783A - Compositions comprenant une co-formulation d'anticorps anti-pd-l1 et anti-ctla-4 - Google Patents

Compositions comprenant une co-formulation d'anticorps anti-pd-l1 et anti-ctla-4

Info

Publication number
MA44783A
MA44783A MA044783A MA44783A MA44783A MA 44783 A MA44783 A MA 44783A MA 044783 A MA044783 A MA 044783A MA 44783 A MA44783 A MA 44783A MA 44783 A MA44783 A MA 44783A
Authority
MA
Morocco
Prior art keywords
ctla
antibody
formulation
compositions containing
compositions
Prior art date
Application number
MA044783A
Other languages
English (en)
Inventor
Jiali Du
Ambarish Shah
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MA44783A publication Critical patent/MA44783A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA044783A 2016-04-25 2017-04-24 Compositions comprenant une co-formulation d'anticorps anti-pd-l1 et anti-ctla-4 MA44783A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662327214P 2016-04-25 2016-04-25

Publications (1)

Publication Number Publication Date
MA44783A true MA44783A (fr) 2019-03-06

Family

ID=60089975

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044783A MA44783A (fr) 2016-04-25 2017-04-24 Compositions comprenant une co-formulation d'anticorps anti-pd-l1 et anti-ctla-4

Country Status (19)

Country Link
US (2) US10421811B2 (fr)
EP (1) EP3448428A4 (fr)
JP (1) JP2019514889A (fr)
KR (1) KR20180135475A (fr)
CN (1) CN109069631A (fr)
AR (1) AR108317A1 (fr)
AU (1) AU2017257505B2 (fr)
BR (1) BR112018071287A2 (fr)
CA (1) CA3020893A1 (fr)
CL (1) CL2018002998A1 (fr)
CO (1) CO2018011195A2 (fr)
IL (1) IL262344A (fr)
MA (1) MA44783A (fr)
MX (1) MX2018012651A (fr)
RU (1) RU2018140960A (fr)
SG (1) SG11201807474SA (fr)
TW (1) TW201740976A (fr)
WO (1) WO2017189433A1 (fr)
ZA (1) ZA201807888B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2612241C (fr) * 2005-07-01 2018-11-06 Medarex, Inc. Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1)
CN105873606B (zh) 2013-09-11 2020-12-29 米迪缪尼有限公司 用于治疗肿瘤的抗b7-h1抗体
EP3757130A1 (fr) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Méthodes de traitement de cancers hématologiques
CA2935423C (fr) 2014-01-24 2023-11-07 Dana-Farber Cancer Institute, Inc. Molecules d'anticorps anti-pd-1 et leurs utilisations
AU2015210750B2 (en) 2014-01-31 2020-08-20 Children's Medical Center Corporation Antibody molecules to TIM-3 and uses thereof
WO2015138920A1 (fr) 2014-03-14 2015-09-17 Novartis Ag Molécules d'anticorps anti-lag-3 et leurs utilisations
EP3142751B1 (fr) * 2014-05-13 2019-08-07 MedImmune Limited Anticorps anti-b7-h1 et anti-ctla -4 pour le traitement du cancer du poumon non à petites cellules
WO2016040882A1 (fr) 2014-09-13 2016-03-17 Novartis Ag Polythérapie par les inhibiteurs de l'egfr
WO2016061142A1 (fr) 2014-10-14 2016-04-21 Novartis Ag Molécules d'anticorps de pd-l1 et leurs utilisations
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
JP6955507B2 (ja) 2015-12-14 2021-10-27 マクロジェニクス，インコーポレーテッド Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
US10059769B2 (en) 2016-06-13 2018-08-28 I-Mab Anti-PD-L1 antibodies and uses thereof
JP2020507596A (ja) * 2017-02-16 2020-03-12 メディミューン，エルエルシー 膀胱癌の抗ｐｄ−ｌ１抗体治療
CA3061050A1 (fr) * 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations stables d'anticorps anti-tigit seuls et en association avec des anticorps du recepteur de mort programmee 1 (pd-1) et leurs procedes d'utilisation
BR112019025188A2 (pt) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
MX2019014265A (es) 2017-06-01 2020-08-03 Compugen Ltd Tratamientos conjuntos triples con anticuerpos.
WO2019206987A1 (fr) * 2018-04-25 2019-10-31 Medimmune Limited Formulations d'anticorps humain anti-pd-l1
CN112041348B (zh) 2018-07-25 2023-09-22 天境生物科技(上海)有限公司 抗cd73抗pd-l1双特异性抗体
CN113056482A (zh) 2018-10-18 2021-06-29 默沙东公司 抗rsv抗体的制剂及其使用方法
CN120842406A (zh) 2018-10-31 2025-10-28 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
KR20230127292A (ko) * 2020-12-30 2023-08-31 아이-맵 바이오파마 컴파니 리미티드 항-cd73 항체의 제제
EP4611898A1 (fr) * 2022-11-04 2025-09-10 Astrazeneca AB Compositions d'anticorps anti-ctla et procédés associés

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2620450T (lt) * 2005-03-08 2019-02-11 Pfizer Products Inc. Anti-ctla-4 antikūnų kompozicijos
WO2007113648A2 (fr) * 2006-04-05 2007-10-11 Pfizer Products Inc. Polythérapie à base d'un anticorps anti-ctla4
EP4209510B1 (fr) * 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
NO2504364T3 (fr) * 2009-11-24 2018-01-06
EP3409289B1 (fr) * 2010-02-26 2020-09-30 Novo Nordisk A/S Compositions contenant un anticorps stable
EP3539982B1 (fr) * 2011-12-23 2025-02-19 Pfizer Inc. Régions constantes d'anticorps modifiés pour conjugaison spécifique à un site, et leurs procédés et utilisations
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
EP3142751B1 (fr) * 2014-05-13 2019-08-07 MedImmune Limited Anticorps anti-b7-h1 et anti-ctla -4 pour le traitement du cancer du poumon non à petites cellules
WO2016030455A1 (fr) * 2014-08-28 2016-03-03 Medimmune Limited Anticorps anti-b7-h1 et anti-ctla -4 pour le traitement du cancer du poumon non à petites cellules
ES2727154T3 (es) * 2014-10-24 2019-10-14 Astrazeneca Ab Combinación
US20160347848A1 (en) * 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia

Also Published As

Publication number Publication date
US10421811B2 (en) 2019-09-24
WO2017189433A1 (fr) 2017-11-02
CL2018002998A1 (es) 2018-12-07
BR112018071287A2 (pt) 2019-02-19
CO2018011195A2 (es) 2018-10-31
ZA201807888B (en) 2019-08-28
RU2018140960A (ru) 2020-05-26
AU2017257505B2 (en) 2020-05-14
EP3448428A1 (fr) 2019-03-06
US20190382494A1 (en) 2019-12-19
EP3448428A4 (fr) 2019-11-27
AU2017257505A1 (en) 2018-12-06
SG11201807474SA (en) 2018-11-29
CA3020893A1 (fr) 2017-11-02
IL262344A (en) 2018-11-29
RU2018140960A3 (fr) 2020-08-03
AR108317A1 (es) 2018-08-08
US20170306025A1 (en) 2017-10-26
CN109069631A (zh) 2018-12-21
KR20180135475A (ko) 2018-12-20
JP2019514889A (ja) 2019-06-06
TW201740976A (zh) 2017-12-01
MX2018012651A (es) 2019-01-30

Similar Documents

Publication Publication Date Title
EP3448428A4 (fr) Compositions comprenant une co-formulation d'anticorps anti-pd-l1 et anti-ctla-4
EP3618871A4 (fr) Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
EP3496753A4 (fr) Formulation d'anticorps anti-pd-1
PL3882275T3 (pl) Przeciwciało dwufunkcyjne anty-pd-1 i anty-vegfa, kompozycja farmaceutyczna i zastosowanie tych przeciwciał
EP3505535A4 (fr) Anticorps monoclonal anti-pd-1, composition pharmaceutique et utilisation de celui-ci
EP3386536A4 (fr) Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation
MA49043A (fr) Formulation stable d'anticorps
MA46525A (fr) Anticorps anti-lag-3 et compositions
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
EP3441086A4 (fr) Anticorps monoclonal anti-pd-1
MA46952A (fr) Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet
DK3541841T3 (da) Anti-PD-1-antistoffer og sammensætninger
MA42447A (fr) Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation
MA43365A (fr) Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
MA46770A (fr) Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
MA71409A (fr) Constructions d'anticorps pour dll3 et cd3
MA55868A (fr) Anticorps monoclonal anti-ctla4 ou son fragment se liant à l'antigène, composition pharmaceutique et son utilisation
DK3368572T3 (da) Anti-pd-1-antistoffer og -sammensætninger
MA49726A (fr) Formulation d'anticorps anti-cgrp
EP3589648A4 (fr) Formulation d'anticorps monoclonal anti-rsv
EP3353213A4 (fr) Nouvel anticorps anti-mésothéline et composition le comprenant
EP3589660A4 (fr) Anticorps anti-pd-l1 et utilisations associées
EP3773718A4 (fr) Compositions et procédés comprenant des anticorps anti-nrp2
MA44054A (fr) Plateforme d'anticorps bispécifique